Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 12

Trial Status

Terminated2
Other1

Role Distribution

Principal Investigator3
PI Rate100%

Activity Timeline

Clinical Trials (3)

NCT05410041Phase 1Withdrawn
Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
PrincipalinvestigatorStart date: 2022-05-10
NCT05271279Early Phase 1Terminated
A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors
Advanced Solid TumorRelapsed/Refractory Lymphoma
PrincipalinvestigatorStart date: 2021-12-24
NCT04973527Phase 1Terminated
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
T Cell LymphomaT-cell Leukemia
PrincipalinvestigatorStart date: 2021-07-02

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Mary Horowitz, MD

Center for International Blood and Marrow Transplant Research

Related
24 trials

Shared therapeutic areas:

Leukemia, Lymphocytic, Chronic, B-CellPrecursor Cell Lymphoblastic Leukemia-LymphomaLymphoma, Non-Hodgkin
Similarity Score13%

Yves Beguin, MD, PhD

CHU-ULg

Related
7 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-Hodgkin
Similarity Score13%

Helen Heslop, MD

Baylor College of Medicine

Related
17 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Similarity Score13%

Jae Park, MD

Memorial Sloan Kettering Cancer Center

Related
17 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Similarity Score9%

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Related
26 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Similarity Score9%

Arnon Nagler, MD

Chaim Sheba Medical Center

Related
12 trials

Shared therapeutic areas:

Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Similarity Score9%

David Avigan, MD

Beth Israel Deaconess Medical Center

Related
17 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Similarity Score9%

Brigitte C Widemann, M.D.

National Cancer Institute (NCI)

Related
19 trials

Shared therapeutic areas:

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Similarity Score4%

Roberto Hernández Martín, MD

Hospital Virgen de la Concha

Related
2 trials

Shared therapeutic areas:

Lymphoma, Non-Hodgkin
Similarity Score4%

Elena Pérez Ceballos, MD

Hospital Morales Meseguer

Related
2 trials

Shared therapeutic areas:

Lymphoma, Non-Hodgkin
Similarity Score4%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT05410041Phase 1PrincipalInvestigator

Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
Withdrawn
NCT05271279Early Phase 1PrincipalInvestigator

A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors

Advanced Solid TumorRelapsed/Refractory Lymphoma
Terminated
NCT04973527Phase 1PrincipalInvestigator

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

T Cell LymphomaT-cell Leukemia
Terminated

All 3 trials loaded